



**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 11 NOV 2004

WIPO

PCT



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 1 September 2004

9 OCT 2003

**The
Patent
Office**

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ100CT03 E843510-2 D02029
P01/7760 0-00 0323702-1

PB60226P

0323702.1

1. Your Reference

2. Patent application number

(The Patent office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

SMITHKLINE BEECHAM CORPORATION
ONE FRANKLIN PLAZA
P. O. BOX 7929
PHILADELPHIA
PENNSYLVANIA 19101
UNITED STATES OF AMERICA

✓ Patents ADP number (if you know it)

10/83 If the applicant is a corporate body, give the country/state of its corporation

05949417004.

USA — Pennsylvania

4 Title of the invention

CHEMICAL COMPOUND

5 Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY
980 GREAT WEST ROAD
BRENTFORD, MIDDLESEX
TW8 9GS, GB

08072555006

6 Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months

Country	Priority application number (if you know it)	Date of Filing (day / month / year)
---------	---	--

7. Divisionals: etc Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f).

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

YES

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Otherwise answer NO See note (d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not count duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheet of this
form

Description	14	<i>14</i>
Claim(s)	1	<i>1</i>
Abstract	-	<i>-</i>
Drawing(s)	-	<i>-</i>

-
10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents(*please specify*)

-
11. I/We request the grant of a patent on the basis of this application

Signature(s)

STEPHANIE A LEAROYD
Steph
Agent for the Applicants

Date: 9 October 2003

-
12. Name and daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

KATHERINE Y EVANS

01 438 768611

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form
- If you have answered "Yes" in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Chemical Compound

The present invention relates to certain novel compounds. In particular, the present invention relates to compounds that activate both the alpha and gamma subtypes of the 5 human peroxisome proliferator activated receptor. The present invention also relates to methods for preparing the compounds and methods for prevention or treatment of PPAR mediated diseases or conditions

Several independent risk factors have been associated with cardiovascular disease. 10 These include hypertension, increased fibrinogen levels, high levels of triglycerides, elevated LDL cholesterol, elevated total cholesterol, and low levels of HDL cholesterol. HMG CoA reductase inhibitors ("statins") are useful for treating conditions characterized by high LDL-c levels. It has been shown that lowering LDL-c is not sufficient for reducing the risk of cardiovascular disease in some patients, particularly those with normal LDL-c 15 levels. This population pool is identified by the independent risk factor of low HDL-c. The increased risk of cardiovascular disease associated with low HDL-c levels has not yet been successfully addressed by drug therapy (i.e., currently there are no drugs on the market that are useful for raising HDL-c >40%). (Bisgaier, C. L.; Pape, M. E. *Curr. Pharm. Des.* 1998, 4, 53-70).

20 Syndrome X (including metabolic syndrome) is loosely defined as a collection of abnormalities including hyperinsulinemia, obesity, elevated levels of triglycerides, uric acid, fibrinogen, small dense LDL-c particles, and plasminogen activator inhibitor 1 (PAI-1), and decreased levels of HDL-c.

25 NIDDM is described as insulin resistance which in turn causes anomalous glucose output and a decrease in glucose uptake by skeletal muscle. These factors eventually lead to impaired glucose tolerance (IGT) and hyperinsulinemia.


30 Peroxisome Proliferator Activated Receptors (PPARs) are orphan receptors belonging to the steroid/retinoid receptor superfamily of ligand-activated transcription factors. See, for example, Willson, T. M. and Wahli, W., *Curr. Opin. Chem. Biol.*, (1997), Vol. 1, pp 235-241.

35 Three mammalian Peroxisome Proliferator-Activated Receptors have been isolated and termed PPAR-alpha, PPAR-gamma, and PPAR-delta (also known as NUC1 or PPAR-beta). These PPARs regulate expression of target genes by binding to DNA sequence elements, termed PPAR response elements (PPRE). To date, PPRE's have been identified in the enhancers of a number of genes encoding proteins that regulate lipid 40 metabolism suggesting that PPARs play a pivotal role in the adipogenic signaling cascade and lipid homeostasis (H. Keller and W. Wahli, *Trends Endocrin. Met.* 291-296, 4 (1993)).

Certain compounds that activate or otherwise interact with one or more of the PPARs have been implicated in the regulation of triglyceride and cholesterol levels in animal models. See, for example, WO 01/40207, WO 01/00603, WO 97/31907, WO 02/46174 (Glaxo Group Ltd et al).

5

WO 02/096895 describes compounds of the following formula:




10 These compounds are described as having PPAR alpha selectivity, useful in the treatment of human PPAR mediated diseases.

15 The present inventors have prepared a further compound which possesses dual activity at human PPAR alpha and human PPAR gamma and as such will be useful in the treatment of human PPAR alpha and/or gamma mediated diseases. In particular it will be useful in treating dyslipidemia. In particular, the ratio of alpha to gamma activity is predicted to provide additional benefits of lipid effects provided by the gamma component in combination with alpha activity without introducing side effects which are often associated with PPAR gamma activity.

20

According to a first aspect of the invention there is provided a compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof:



(1)

25

In another aspect, the present invention discloses a method for prevention or treatment of a human PPAR ("hPPAR") mediated disease or condition comprising administration of a therapeutically effective amount of a compound of this invention. hPPAR mediated diseases or conditions include dyslipidemia including associated diabetic dyslipidemia and

- mixed dyslipidemia, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesterolemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lining and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, bulimia, and anorexia nervosa. In particular, the compounds of this invention are useful in the treatment and prevention of cardiovascular diseases and conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.
- In another aspect, the present invention provides pharmaceutical compositions comprising the compound of the invention, preferably in association with a pharmaceutically acceptable diluent or carrier.
- In another aspect, the present invention provides the compound of the invention for use in therapy, and in particular, in human medicine.
- In another aspect, the present invention provides the use of the compound of the invention for the manufacture of a medicament for the treatment of a hPPARmediated disease or condition.
- In another aspect, the present invention provides a method of treatment of a patient suffering from a hPPARmediated disease or condition comprising the administration of therapeutically effective amount of the compound of the invention.
- As used herein, "the compound of the invention" means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolyzable ester thereof.
- While hydrolyzable esters are included in the scope of this invention, the acids are preferred because the data suggests that while the esters are useful compounds, it may actually be the acids to which they hydrolyze that are the active compounds. Esters that hydrolyze readily can produce the carboxylic acid in the assay conditions or in vivo. Generally the carboxylic acid is active in both the binding and transient transfection assays, while the ester does not usually bind well but is active in the transient transfection assay presumably due to hydrolysis. Preferred hydrolysable esters are C₁₋₆ alkyl esters wherein the alkyl group may be straight chain or branched chain. Methyl or ethyl esters are more preferred.
- The compound of formula (I) is a selective dual agonist of PPAR alpha and gamma. As used herein, by "agonist", or "activating compound", or "activator", or the like, is meant those compounds which have a pKi of at least 6.0 preferably at least 7.0 to the relevant PPAR, for example hPPAR α in the binding assay described below, and which achieve at

least 50% activation of the relevant PPAR relative to the appropriate indicated positive control in the transfection assay described below at concentrations of 10-5 M or less.

As used herein, a "selective dual hPPAR alpha/gamma agonist" is a hPPARalpha/gamma

5 agonist whose EC₅₀ for PPARalpha and PPAR gamma is at least 10 fold lower than its EC₅₀ for PPAR delta. EC₅₀ is defined in the transfection assay described below and is the concentration at which a compound achieves 50% of its maximum activity.

It will be appreciated by those skilled in the art that the compounds of the present invention

10 may also be utilized in the form of a pharmaceutically acceptable salt or solvate thereof. The physiologically acceptable salts of the compounds of formula (I) include conventional salts formed from pharmaceutically acceptable inorganic or organic acids or bases as well as quaternary ammonium acid addition salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic and the like. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable salts. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine salts. References hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable salts and solvates.

The compound of the invention and its pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

30 While it is possible that compounds of the present invention may be therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

40 Accordingly, the present invention further provides for a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients.

The formulations include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon for example the condition and disorder

- 5 of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the compounds ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient 10 with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping 15 the product into the desired formulation.

Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric 15 administration) each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active 20 ingredient may also be presented as a bolus, electuary or paste.

- 20 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with other conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for 25 example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulfate. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid 30 diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. The tablets may be coated according to methods well-known in the art.

Alternatively, the compounds of the present invention may be incorporated into oral liquid 35 preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example. Moreover, formulations containing these compounds may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid 40 preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene

glycol or ethyl alcohol; and preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid. Such preparations may also be formulated as suppositories, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

- 5 Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

- 10 The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of a sterile liquid carrier, for example, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be
15 prepared from sterile powders, granules and tablets of the kind previously described.

Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, hard fat or polyethylene glycol.

- 20 Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.

- 25 The compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for
30 example, as a sparingly soluble salt.

In addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

- 35 It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms. Moreover, it will be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the
40 condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of 0.02-5000 mg per day, preferably 1-1500 mg per day. The desired

dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day. The formulations according to the invention may contain between 0.1-99% of the active ingredient, conveniently from 30-95% for tablets and capsules and 3-50% for liquid preparations.

The compound of formula (I) for use in the instant invention may be used in combination with other therapeutic agents for example, statins and/or other lipid lowering drugs for example MTP inhibitors and LDLR upregulators. The compounds of the invention may also be used in combination with antidiabetic agents, e.g. metformin, sulfonylureas and/or PPAR gamma agonists (for example thiazolidinediones such as e.g. Pioglitazone and Rosiglitazone). The compounds may also be used in combination with antihypertensive agents such as calcium channel antagonists and ACE inhibitors. The invention thus provides in a further aspect the use of a combination comprising a compound of formula (I) with a further therapeutic agent in the treatment of a hPPAR alpha mediated disease.

When the compounds of formula (I) are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.


The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

When a compound of formula (I) is used in combination with a second therapeutic agent active against the same hPPAR mediated disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.


Compounds of this invention may be conveniently prepared by a general process wherein a moiety like (A) is acylated with an ester (B). R in formula (B) is C₁₋₆alkyl (preferably a C₂ alkyl). Note this synthesis is preferably carried out with the acid group of moiety A protected by R to avoid decarboxylation of the acid. Thus R is conveniently C₁₋₆ alkyl

which can be hydrolyzed off to give an acid of Formula (I), or if readily hydrolyzable, the resulting ester can be administered.




5

In particular, the compound of formula (I) may be obtained as described in the reaction scheme below.



EXAMPLES

10 The invention will now be demonstrated by the following intermediates and examples which should not be construed as constituting a limitation thereto.



Intermediate 1: 1-[4-(1-methylethyl)phenyl]-2-propanone

5 513 ml of 2,4-pentanedione was slowly added to a solution of 280.5 g of KOH in 2.3 L of ethanol cooled at 5°C, over 2.5h.. The mixture was stirred at 5°C for 1h then heated to room temperature and stirred for 2h. The mixture was concentrated to dryness to give 639 g of the potassium salt of 2,4-pentanedione used without further purification. Yield = 92.6%.


10 Under nitrogen and at room temperature, 86.9 g of copper iodide and 630 g of potassium salt of 2,4-pentanedione was added to a solution of 181.8 g of 1-bromo-4-(1-methylethyl)benzene in DMF. The mixture was stirred at 100°C for 16h then, after cooling to 10°C, 2L of H₂O were added. The aqueous layer was extracted 4 times with pentane. The organic layer was washed with HCl 1N and dried on MgSO₄. After filtration and evaporation under vacuum , the oily residue was purified on silicagel (Cyclohexane/AcOEt = 95/5) to give after evaporation 76.9 g of a colorless oil. Yield = 47.8%.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255

Intermediate 3: Ethyl amino(thioxo)acetate


3 ml g of triethylamine was added to a solution of 100 g of Ethylcyanoformate in 400 mL of diethyl ether. The reaction mixture was cooled to 0°C and H₂S was bubbled for 1h. After the end of addition the mixture was allowed to return to room temperature and stirred overnight. Then the mixture was poured in 900 ml of HCl 1N. After stirring for 0.5 h and decantation, the aqueous layer was extracted twice with 200 ml of diethyl ether. The combined organic layer was washed 3 times with 300 ml of H₂O. After drying on magnesium sulphate, the organic layer was filtered and concentrated to dryness to give 109.5 g of yellow crystals which are used in the next step without further purification. yield = 81.6%.

¹H-NMR (CDCl₃) : δ 8.2 (b, 1H) ; 7.7 (b, 1H) ; 4.3 (q, 2H) ; 1.34 (t, 3H).

Intermediate 4: Ethyl 4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazole-2-carboxylate

95.4 g of Intermediate 3 (ethyl amino(thioxo)acetate) was added to a solution of 183 g of Intermediate 2 (1-bromo-1-[4-(1-methylethyl)phenyl]-2-propanone) in 2 L of EtOH. The reaction mixture was stirred overnight at room temperature then heated at reflux for 45 minutes. The mixture was concentrated to dryness and the residue is purified on silicagel (Cyclohexane/AcOEt = 9/1 then 8/2) to give after evaporation 108.3 g of an orange oil . Yield = 52.3%.

¹H-NMR (CDCl₃) : δ 7.42 (d, 2H) ; 7.33 (d, 2H) ; 4.5 (q, 2H) ; 2.98 (h, 1H) ; 2.61 (s, 3H) ; 1.46 (t, 3H) ; 1.31 (d, 6H).


Intermediate 5: Ethyl 2-[(4-cyanophenyl)oxy]-2-methylpropanoate

278.6g of K₂CO₃ was added to a solution of 200 g para hydroxybenzonitrile in 2 L of acetonitrile. The mixture was refluxed for 1h, then 250 ml of ethyl bromoisobutyrate was slowly added over 1 hour. The reaction was followed by ttc. After 2 days of reflux, 140 g of

K₂CO₃ and 126 ml of ethyl bromoisobutyrate were added. After 6 h of reflux, 140 g of K₂CO₃ and 126 ml of ethyl bromoisobutyrate were added. After 3 days of reflux, 140 g of K₂CO₃ and 126 ml of ethyl bromoisobutyrate were added. After 6 h of reflux and return to room temperature, the solid material was removed by filtration and washed with 5 acetonitrile. The filtrate was concentrated to dryness then treated with 800 ml of NaOH 1N. After stirring for 15 minutes, the aqueous mixture was extracted twice with ethyl ether. The organic layer was washed with NaOH 1N and brine. After drying on magnesium sulphate, the organic layer was filtered and concentrated to dryness to give 364 g of an oil. yield = 92.9%.

10


¹H NMR (CDCl₃): δ 7.37 (d, 2H), 6.68 (d, 2H), 4.06 (q, 2H), 1.48 (s, 6H), 1.05 (t, 3H).



15 Intermediate 6: Ethyl 2-[(4-(aminomethyl)phenyl]oxy}-2-methylpropanoate

In a hydrogenator of 1L, a mixture of 62.3 g of Intermediate 5: (Ethyl 2-[(4-cyanophenyl)oxy]-2-methylpropanoate), 47 ml of glacial acetic acid and 3.1 g of Pd/C 10% in 310 ml of ethyl alcohol was hydrogenated over 2 bars of hydrogen and at room 20 temperature. After filtration of the catalyst, the solution was evaporated to dryness to give the acetic salt of Ethyl 2-[(4-(aminomethyl)phenyl]oxy}-2-methylpropanoate (oily residue). The residue was poured in 350 ml of water 500 ml of ethyl acetate. The biphasic mixture was cooled to 10°C and treated with NaOH 1N (to pH = 11). After decantation, the aqueous layer was extracted twice with 200 ml of ethyl acetate. The combined organic 25 layer was washed with 300 ml of brine. After drying on magnesium sulphate, the organic layer was filtered and concentrated to dryness to give 60.1 g of a colorless oil crude which is used in the next step without further purification. yield = 94.8%.


30 ¹H NMR (CDCl₃): δ 7.07 (d, 2H), 6.71 (d, 2H), 4.12 (q, 2H), 3.68 (m, 2H), 1.47 (s, 6H), 1.15 (t, 3H).



Intermediate 7: Ethyl 2-methyl-2-[(4-{[{4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazol-2-yl}carbonyl]amino]methyl}phenyl)oxy]propanoate

229 g of Intermediate 6 (Ethyl 2-{{[4-(aminomethyl)phenyl]oxy}-2-methylpropanoate) and
 5 420 ml of diisopropylethylamine. Were added to a solution of 139.6 g of Intermediate 4 (Ethyl 4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazole-2-carboxylate) in 1.5 L of EtOH. The reaction mixture was heated at reflux for 3 days, then a solution of 1 equiv of Ethyl 2-{{[4-(aminomethyl)phenyl]oxy}-2-methylpropanoate in 250 ml of EtOH was added and the reaction mixture was heated at reflux for a further day. This operation was repeated once
 10 more. The mixture was concentrated to dryness and 2 L of H₂O was added to the residue then NaOH 1N until a pH = 11 was obtained. The aqueous layer was extracted with Ethyl acetate. The organic layer was washed twice with HCl 1N, saturated solution of NaHCO₃ and brine. The organic layer was dried with MgSO₄. After filtration and evaporation under vacuum, the oily residue obtained was purified on silicagel (Cyclohexane/AcOEt = 9/1) to
 15 give after evaporation 142.9 g of an oil which crystallized slowly. Yield = 61.6%.

¹H-NMR (CDCl₃) : δ 7.42 (t, 1H) ; 7.31 (d, 2H) ; 7.23 (d, 2H) ; 7.17 (d, 2H) ; 6.75 (d, 2H) ;
 4.5 (d, 2H) ; 4.17 (q, 2H) ; 2.88 (h, 1H) ; 2.41 (s, 3H) ; 1.52 (s, 6H) ; 1.22-1.17 (m, 9H).



20 Example 1: 2-methyl-2-[(4-{[{4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazol-2-yl}carbonyl]amino}methyl]phenyl)oxy]propanoic acid

was added 595 mL of NaOH 1N was added to a solution of 142.9 g of Intermediate 7
 25 (Ethyl-2-methyl-2-[(4-{[{4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazol-2-yl}carbonyl]amino}methyl]phenyl)oxy]propanoate) in 2 L of EtOH. The reaction mixture was heated at reflux for 1 H. EtOH was evaporated under vacuum and 1 L of H₂O was added then HCl 1N until pH = 1 was obtained. A white precipitate appeared and the mixture was stirred at 5°C for 15 minutes to obtain complete precipitation. The white
 30 precipitate was filtered then washed with water. After drying under vacuum the white powder obtained was re-crystallised in toluene (1g of compound in 1.7 ml of toluene) to afford 88.2 g of off white crystals. Yield = 65.5%. Mp = 130.8°C.

¹H NMR (CDCl₃) : δ 7.86 (t, 1H) ; 7.39 (d, 2H) ; 7.33-7.28 (m, 4H) ; 6.93 (d, 2H) ; 4.6 (d, 2H) ; 2.98 (h, 1H) ; 2.5 (s, 3H) ; 1.63 (s, 6H) ; 1.31 (d, 6H)

BINDING AND TRANSFECTION ASSAYSBinding Assay:

Compounds were tested for their ability to bind to hPPAR gamma hPPARalpha or PPARdelta using a Scintillation Proximity Assay (SPA). The PPAR ligand binding domain (LBD) was expressed in E. coli as polyHis tagged fusion proteins and purified. The LBD was then labelled with biotin and immobilised on streptavidin-modified scintillation proximity beads. The beads were then incubated with a constant amount of the appropriate radioligand (5-[4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl]-thiazolidine-2,4-dione (*J.Med.Chem.* 1994, 37(23), 3977), for PPARgamma), and labelled GW 2433 (see Brown, P. J et al. *Chem. Biol.*, 4, 909-918 (1997), for the structure and synthesis of this ligand) for PPAR alpha and PPAR delta) and variable concentrations of test compound, and after equilibration the radioactivity bound to the beads was measured by a scintillation counter. The amount of nonspecific binding, as assessed by control wells containing 50 μ M of the corresponding unlabeled ligand, was subtracted from each data point. For each compound tested, plots of ligand concentration vs. CPM of radioligand bound were constructed and apparent KI values were estimated from nonlinear least squares fit of the data assuming simple competitive binding. The details of this assay have been reported elsewhere (see, Blanchard, S. G. et. al. Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor gamma Ligand Binding Domain. *Anal. Biochem.*, 257, 112-119 (1998)).

Transfection assay:

Compounds were screened for functional potency in transient transfection assays in CV-1 cells for their ability to activate the PPAR subtypes (transactivation assay). A previously established chimeric receptor system was utilized to allow comparison of the relative transcriptional activity of the receptor subtypes on the same target gene and to prevent endogenous receptor activation from complicating the interpretation of results. See, for example, Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), *J. Biol. Chem.*, 270, 12953-6 (1995). The ligand binding domains for murine and human PPAR alpha, PPAR gamma, and PPAR delta were each fused to the yeast transcription factor GAL4 DNA binding domain. CV-1 cells were transiently transfected with expression vectors for the respective PPAR chimera along with a reporter construct containing five copies of the GAL4 DNA binding site driving expression of secreted placental alkaline phosphatase (SPAP) and beta-galactosidase. After 16 h, the medium was exchanged to DME medium supplemented with 10% delipidated fetal calf serum and the test compound at the appropriate concentration. After an additional 24h, cell extracts were prepared and assayed for alkaline phosphatase and β -galactosidase activity. Alkaline phosphatase activity was corrected for transfection efficiency using the beta-galactosidase activity as an internal standard (see, for example, Kliewer, S. A., et. al. *Cell* 83, 813-819 (1995)). Rosiglitazone (BRL 49653) was used as a positive control in the hPPAR gamma assay. The positive control in the hPPAR alpha assays was 2-4-[2-(3-[4-fluorophenyl]-1-heptylureido)ethyl]-phenoxy-(2-methyl propionic acid (WO 97/36579). The positive control

for PPAR delta assays was 2-{2-methyl-4-[({4-methyl-2-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid (WO 01/00603). The positive control was (5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione (*J.Med.Chem.* 1994, 37(23), 3977), for PPAR γ ..

5

Activities in three hPPAR subtypes are reported in the table and are expressed in micromolar.


Example	EC50 μ M HPPAR α	EC50 μ M HPPAR δ	EC50 μ M HPPAR γ
Example 1	0.008	6.1	0.19

- 10 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features described herein. This may take the form of product, composition, process or use claims any include, by way of example and without limitation, one or more of the following claims.

What is claimed is:

1. A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof

5



(1)

2. A compound according to claim 1 for use in therapy.

- 10 3. A pharmaceutical composition comprising a compound according to claim 1.

4. A pharmaceutical composition according to claim 3 further comprising a pharmaceutically acceptable diluent or carrier.

- 15 5. Use of a compound according to any of claim 1 for the manufacture of a medicament for the treatment of a hPPAR disease or condition.

- 20 6. Use according to claim 5 wherein the hPPAR mediated disease or condition is dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa

- 25 7. A method of treating a hPPAR mediated disease or condition in a patient comprising the administration of a therapeutically effective amount of a compound according to claim 1.

- 30 8. A method according to claim 7 wherein the hPPAR mediated disease or condition is dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa.

DCA
PCT/EP2004/011386

